The Waltham, Massachusetts facility met nine system criteria under the Initiative for Certification of Manufacturing Capabilities program, the company said.
The agency’s new two-phase regulatory framework seeks to strengthen domestic supply chain and reduce foreign dependence on active pharmaceutical ingredients.